Chemomab Therapeutics (CMMB) Free Cash Flow (2017 - 2023)
Chemomab Therapeutics' (CMMB) quarterly Free Cash Flow came in at -$3.7 million in Q4 2023, up 36.23% YoY from -$2.7 million in Q4 2022, and up 28.71% on a QoQ basis from -$5.2 million in Q3 2023.
Chemomab Therapeutics (CMMB) Free Cash Flow (2017 - 2023) Analysis & Trends
Chemomab Therapeutics (CMMB) has 7 years of Free Cash Flow data on file, last reported at -$3.7 million in Q4 2023.
- Quarterly Free Cash Flow rose 36.23% year-over-year to -$3.7 million in Q4 2023, while the trailing twelve-month figure through Sep 2024 was -$3.7 million (up 85.53% YoY) and the FY2025 annual result came in at -$11.1 million, up 27.64% from the prior year.
- Free Cash Flow advanced to -$3.7 million in Q4 2023, from -$5.2 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of -$880000.0 in Q2 2020 to a low of -$7.5 million in Q2 2023.
- A 5-year average of -$3.9 million and a median of -$3.7 million in 2019 frame the typical range for Free Cash Flow.
- Annual changes were most pronounced in 2020 — Free Cash Flow jumped 77.14% — and 2021, when it slumped 548.75%.
- Tracing CMMB's Free Cash Flow over 5 years: stood at -$4.6 million in 2019, then surged by 66.12% to -$1.6 million in 2020, then tumbled by 94.6% to -$3.0 million in 2021, then tumbled by 92.8% to -$5.8 million in 2022, then soared by 36.23% to -$3.7 million in 2023.
- The last three Free Cash Flow figures came in at -$3.7 million (Q4 2023), -$5.2 million (Q3 2023), and -$7.5 million (Q2 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | Chemomab Therapeutics | 13.62 Mn | 3.25 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | -3.72 Mn |
| Dec 31, 2023 | -3.72 Mn |
| Sep 30, 2023 | -5.22 Mn |
| Sep 30, 2023 | -5.22 Mn |
| Jun 30, 2023 | -7.48 Mn |
| Jun 30, 2023 | -7.48 Mn |
| Mar 31, 2023 | -7.19 Mn |
| Mar 31, 2023 | -7.19 Mn |
| Dec 31, 2022 | -5.84 Mn |
| Dec 31, 2022 | -5.84 Mn |
| Sep 30, 2022 | -5.21 Mn |
| Sep 30, 2022 | -5.21 Mn |
| Jun 30, 2022 | -5.66 Mn |
| Jun 30, 2022 | -5.66 Mn |
| Mar 31, 2022 | -3.73 Mn |
| Mar 31, 2022 | -3.73 Mn |
| Dec 31, 2021 | -3.03 Mn |
| Dec 31, 2021 | -3.03 Mn |
| Sep 30, 2021 | -2.58 Mn |
| Sep 30, 2021 | -2.58 Mn |